AbbVie vs Aspire-Lakewood Holdings
AbbVie (ABBV) and Aspire-Lakewood Holdings (ASBP) side by side: how big they are, what they earn, how their shares have moved and what insiders, members of Congress and funds reported. Figures from filings and closing prices; none of this is a view on either stock.
- Market value
- $506B
- Last close
- $286.20
- 12 months
- +24.7%
- Market value
- $10M
- Last close
- $7.13
- 12 months
- −93.9%
At a glance
- AbbVie earns 76% of its revenue in the United States, Aspire-Lakewood Holdings 99%.
- By market value, AbbVie ($505.9B) is about 50588 times Aspire-Lakewood Holdings ($10M).
- Over the last 12 months AbbVie's share price moved +24.7% and Aspire-Lakewood Holdings's −93.9%; against the S&P 500 that is +19.0 points and −99.6 points.
- In their last fiscal years AbbVie kept 6.9% of revenue as net income and Aspire-Lakewood Holdings -394725.1%.
- In the last 90 days insiders reported 0 open-market purchases at AbbVie and 0 at Aspire-Lakewood Holdings; members of Congress disclosed 1 trade in AbbVie and 0 in Aspire-Lakewood Holdings.
- Next results: AbbVie Feb 2, 2027, Aspire-Lakewood Holdings not announced.
How each one makes money: AbbVie revenue · Aspire-Lakewood Holdings revenue
Share prices on one chart
AbbVie and Aspire-Lakewood Holdings, and up to three more you add, drawn on the same scale so you can see which moved more.
Face to face
The figures that separate the two, drawn to the same scale. Every figure is also in the table below.
Size
Market value
Revenue, last fiscal year
Net income, last fiscal year
Every figure
| AbbVie ABBVNYSE · Pharmaceuticals | Aspire-Lakewood Holdings ASBPNASDAQ · Pharmaceutical Preparations | |
|---|---|---|
| Size and profitability | ||
| Market value | $506B | $10M |
| Revenue, last fiscal year | $61.2B | $6.2K |
| Net income, last fiscal year | $4.23B | −$24.5M |
| Net marginNet income as a share of revenue | 6.9% | -394725.1% |
| Free cash flow | $17.8B | |
Prices are end-of-day closes, and fundamentals are the companies' last annual figures from their SEC filings: a − or + in the table is a fact of the filing or the close, not a forecast. Market value is the company-level figure at the last close. Counts are of records OQRO holds, by their date; insider history since 2006 comes from the SEC's insider transactions data sets and every filing since. Planned sales under a 10b5-1 plan are counted like other sales.
Compare with another company
AbbVie against
Common questions
How is AbbVie different from Aspire-Lakewood Holdings?
AbbVie (ABBV) is in Pharmaceuticals on NYSE, with $61.2B of revenue in its last fiscal year and a net margin of 6.9%. Aspire-Lakewood Holdings (ASBP) is in Pharmaceutical Preparations on NASDAQ, with $6.2K of revenue in its last fiscal year and a net margin of -394725.1%. AbbVie earns 76% of its revenue in the United States, Aspire-Lakewood Holdings 99%. The table above sets their figures side by side; it compares filings and is not a view on either stock.
How do AbbVie and Aspire-Lakewood Holdings compare in size?
AbbVie has the larger market value: AbbVie $506B and Aspire-Lakewood Holdings $10M, at the last close.
Whose share price rose more over the last 12 months, ABBV or ASBP?
Over the last 12 months AbbVie moved +24.7% and Aspire-Lakewood Holdings −93.9%. Past price moves say nothing about the future.
Which has had more insider buying, AbbVie or Aspire-Lakewood Holdings?
Since 2006, AbbVie insiders reported 25 open-market purchases against 4 for Aspire-Lakewood Holdings. These are counts of what was filed, not a view on either stock.
Do members of Congress trade ABBV or ASBP?
In the last 12 months, members of Congress disclosed 9 trades in AbbVie (ABBV) and 0 in Aspire-Lakewood Holdings (ASBP).
When did insiders last buy ABBV and ASBP?
See the record behind any of these
A free account opens the full history of every insider and company since 2006, the screener, alerts, Congress trades and fund moves.
AbbVie pageAspire-Lakewood Holdings pageRare insider trades this weekAll comparisons
https://oqro.io/compare/abbv-vs-asbp







